Dolphin Medical board meets Sep 21, 2026 on chair change

What the company has told the exchange

Dolphin Medical Services Limited has informed the BSE that its Board of Directors will meet on September 21, 2026. The meeting has been called to consider proposed changes to the company’s leadership and promoter categorisation. The company’s intimation was made under Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The board meeting is scheduled to begin at 11:00 am. At this stage, the proposals are not approved, and the outcome will depend on the board’s decision and any required legal or regulatory approvals. Investors typically track such disclosures because changes in chairman, director roles, and promoter classification can affect governance structure and compliance responsibilities.

Meeting date and timing

The scheduled board meeting is on September 21, 2026 at 11:00 am. The company’s exchange filing indicates the agenda is focused on leadership and promoter group matters rather than operational or financial results.

The company has framed the matters as “subject to applicable approvals,” indicating that even if the board agrees, the changes may require further clearances or filings. The exchange outcome filing after the meeting is expected to clarify whether approvals were granted and what the effective dates are.

Appointment proposal: Amarandhar Reddy Kotha as chairman

One of the main agenda items is the appointment of Mr. Amarandhar Reddy Kotha (DIN: 07425226) as Chairman and Promoter Director of the company. The disclosure states this appointment is subject to applicable legal approvals.

A chairman appointment, particularly when combined with “promoter director” status, is viewed as a governance milestone because it can signal a formal leadership position for the promoter group on the board. However, the exchange disclosure makes it clear that the appointment is only for consideration at the meeting and is not yet effective.

Reclassification proposal: Rajesh Kumar Mallour to promoter category

The board will also consider changing the category of Mr. Rajesh Kumar Mallour (DIN: 07425226) from “Professional” to “Promoter,” subject to requisite approvals. Reclassification matters are closely watched because promoter categorisation has disclosure implications under listing regulations and can influence how shareholding, control, and related-party considerations are interpreted.

The company has not stated an effective date for the proposed reclassification in the disclosed agenda. That detail, along with confirmation of any regulatory steps completed, is typically provided in the post-meeting filing.

Committee reconstitution and filings

If the board approves the proposals, Dolphin Medical Services also plans to reconstitute its board committees to reflect the revised board composition. The filing further notes that the board will authorise Mr. Mallour to make necessary filings with regulatory authorities regarding the reclassification of Promoter and Promoter Group.

Committee reconstitution is a standard follow-through step after director role changes. It helps align the audit, nomination and remuneration, stakeholder relations, and other committees with the updated board structure and applicable governance norms.

Why these governance items matter to investors

Leadership appointments and promoter reclassification are governance events that can change how control and accountability are represented in public disclosures. In this case, the company’s stated focus is clarity around the chairman role and promoter categorisation.

The company has also signalled that approvals and compliance steps are part of the process, which means investors will need to rely on subsequent exchange filings for confirmation. Until the board takes a decision and the company completes any required procedures, the proposals remain under consideration.

Background: stake acquisition and open offer context

The governance proposals come after a series of acquisition-related updates involving Mr. Amarandhar Reddy Kotha and Mr. Mallour Rajesh Kumar. As per the provided information, the two completed the acquisition of an additional 20.95% stake in Dolphin Medical Services Limited from Gude Venkata Mohan Prasad and Lakshmi Sudha Madala. That transaction was referenced at INR 5.7 million.

Separately, they completed the acquisition of 0.12% stake in the company for INR 0.09 million. The information also states that Dolphin Medical Services announced a post-offer advertisement for its open offer and that the acquirers, along with existing promoters, now hold 26.57% of the company’s equity. This includes 0.12% acquired through the open offer and 20.95% acquired through a Share Purchase Agreement.

The details also reference that the open offer, led by acquirers Amarandhar Reddy Kotha and Mallour Rajesh Kumar, acquired 26% of the company at ₹4.80 per share, increasing their holding from 0.01% to 26%. Post-offer, public shareholding is stated at 73.43%, with total shareholding at 100%.

Key facts at a glance

Ownership and offer-related figures mentioned

What to watch after September 21

The key next update will be the company’s post-meeting exchange filing, which should confirm whether the board approved the appointment of Mr. Kotha as chairman and promoter director, and whether Mr. Mallour’s reclassification was approved. The same filing is also expected to clarify effective dates and the status of required approvals and regulatory compliances.

If approvals are granted, investors may also look for disclosures on reconstituted committee memberships and any subsequent regulatory filings made in relation to promoter and promoter group categorisation.